Tianjin Chase Sun Pharmaceutical Co.,Ltd
As of 20 November 2026, for the company name Tianjin Chase Sun Pharmaceutical Co.,Ltd as recorded, 4 applications with this name as first applicant are listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 23 records, across 16 drug names; since 24 August 2026, the records list Accepted: 1 application; the chemical-drug catalogue lists 17 active records with this name as holder; 16 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.
Drug filings
23 acceptance records as first applicant, grouped into 16 source drug names. Source data as of 2026/11/20.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Colistimethate Sodium for Injection 2 records · Latest accepted 2026/11/19
Generic · 2
Nafamostat Mesilate for Injection 2 records · Latest accepted 2026/07/06
Generic · 2
Moxifloxacin Hydrochloride And Sodium Chloride Injection 2 records · Latest accepted 2026/02/25
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2600385 | Supplement | 2026/02/25 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Yichang Sanxia Pharmaceutical Co.,Ltd.; Shandong Hua Lu Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2400581 | Supplement | 2024/04/30 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Yichang Sanxia Pharmaceutical Co.,Ltd.; Shandong Hua Lu Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Upadacitinib Sustained-release Tablets 1 records · Latest accepted 2025/12/06
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2504198 | Generic | 2025/12/06 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Isavuconazonium Sulfate for Injection 1 records · Latest accepted 2025/09/05
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2503292 | Generic | 2025/09/05 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Jiangsu Hai An Pharma Co., Ltd. romanized | CDE ↗ |
Landiolol Hydrochloride for Injection 1 records · Latest accepted 2025/01/01
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHL2400285 | Generic | 2025/01/01 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Terlipressin for Injection 1 records · Latest accepted 2024/12/28
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404610 | Generic | 2024/12/28 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CDE ↗ |
Thymalfasin for Injection 1 records · Latest accepted 2024/12/27
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2450637 | Supplement | 2024/12/27 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CDE ↗ |
艾姆地芬片 · No verified English name 3 records · Latest accepted 2023/12/13
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2300257 | Supplement | 2023/12/13 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
| CXHB2300037 | Supplement | 2023/02/08 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
| CXHB2101154 | Supplement | 2021/12/14 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Sodium Ibandronate Injection 2 records · Latest accepted 2023/11/29
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2350899 | Supplement | 2023/11/29 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CDE ↗ |
| CYHB2350898 | Supplement | 2023/11/29 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | CDE ↗ |
注射用甲磺酸苦柯胺B · No verified English name 1 records · Latest accepted 2023/11/18
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2300235 | Supplement | 2023/11/18 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Ketorolac Tromethamine Injection 1 records · Latest accepted 2023/03/31
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2350306 | Supplement | 2023/03/31 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Sarpogrelate Hydrochloride Tablets 1 records · Latest accepted 2022/12/30
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2202334 | Supplement | 2022/12/30 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Valsartan and Amlodipine Tablets(I) 1 records · Latest accepted 2022/09/24
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201606 | Generic | 2022/09/24 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Rocuronium Bromide Injection 2 records · Latest accepted 2022/08/16
Supplement · 2
血必净注射液 · No verified English name 1 records · Latest accepted 2021/12/20
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYZB2102140 | Supplement | 2021/12/20 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
Changes in the last 90 days
1 events from 2026/08/24 to 2026/11/21. CDE data as of 2026/11/20; NMPA data as of 2026/11/20.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Accepted: 1 application
- 2026/11/19Accepted
Colistimethate Sodium for Injection
CYHS2602859
Fact date: 2026/11/19 · Date added to this site: 2026/11/20
View source ↗
Under review
4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Colistimethate Sodium for Injection | CYHS2602859 | Generic | 2026/11/19 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Sichuan Huiyu Pharmaceutical Co., Ltd. | CDE ↗ |
| Nafamostat Mesilate for Injection | CYHS2601589 | Generic | 2026/07/06 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Wuhan Ren Fu Pharma Co., Ltd. romanized | CDE ↗ |
| Upadacitinib Sustained-release Tablets | CYHS2504198 | Generic | 2025/12/06 | Tianjin Chase Sun Pharmaceutical Co.,Ltd | CDE ↗ |
| Isavuconazonium Sulfate for Injection | CYHS2503292 | Generic | 2025/09/05 | Tianjin Chase Sun Pharmaceutical Co.,Ltd; Jiangsu Hai An Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
17 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | NMPA approval no. | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Thymalfasin for Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | 国药准字H20223429 | 2025/12/24 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Sodium Ibandronate Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | 国药准字H20247304 | 2024/12/05 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Sodium Ibandronate Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | HARBIN MEDISAN PHARMACEUTICAL CO.,LTD. | 国药准字H20203187 | 2024/12/05 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Ketorolac Tromethamine Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20183297 | 2024/11/20 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Valsartan and Amlodipine Tablets(I) | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20243509 | 2024/04/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Rocuronium Bromide Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213910 | 2023/09/15 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Rocuronium Bromide Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213909 | 2023/09/15 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Nadroparin Calcium Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20223184 | 2022/03/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Nadroparin Calcium Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20223185 | 2022/03/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Enoxaparin Sodium Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213973 | 2021/12/31 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Enoxaparin Sodium Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213972 | 2021/12/31 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Pramipexole Dihydrochloride Prolonged-release Tablets | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213594 | 2021/07/20 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Pramipexole Dihydrochloride Prolonged-release Tablets | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213595 | 2021/07/20 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Pramipexole Dihydrochloride Tablets | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213572 | 2021/07/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Pramipexole Dihydrochloride Tablets | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213573 | 2021/07/12 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sarpogrelate Hydrochloride Tablets | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20213388 | 2021/05/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Fasudil Hydrochloride Injection | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Tianjin Chase Sun Pharmaceutical Co.,Ltd | 国药准字H20040356 | 2021/04/28 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
16 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 醋酸特利加压素 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20240000299 | I | 2024/04/17 | CDE ↗ |
| 酮咯酸氨丁三醇 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20220001133 | A | 2024/07/09 | CDE ↗ |
| 甲苯磺酰胺 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20210001311 | A | 2022/11/21 | CDE ↗ |
| 盐酸沙格雷酯 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20190021607 | A | 2026/01/24 | CDE ↗ |
| 盐酸法舒地尔 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20190009608 | A | 2025/07/24 | CDE ↗ |
| 盐酸普拉克索 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20180001756 | A | 2025/09/20 | CDE ↗ |
| 盐酸法舒地尔 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170002009 | I | — | CDE ↗ |
| 肝素钠 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000916 | I | — | CDE ↗ |
| L-苹果酸 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000857 | A | 2023/12/21 | CDE ↗ |
| 罗库溴铵 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000841 | A | 2023/12/21 | CDE ↗ |
| 盐酸替罗非班 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000825 | A | 2023/12/21 | CDE ↗ |
| 胸腺法新 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000824 | A | 2025/02/24 | CDE ↗ |
| 伊班膦酸钠 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000515 | A | 2025/12/31 | CDE ↗ |
| 阿立哌唑 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000442 | I | — | CDE ↗ |
| 盐酸莫西沙星 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000298 | A | 2024/11/26 | CDE ↗ |
| 硫酸氢氯吡格雷 · No verified English name | Tianjin Chase Sun Pharmaceutical Co.,Ltd | Y20170000116 | A | 2023/12/21 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/20
- Chemical-drug catalogue
- Last successful update: 2026/11/20
- API registrations
- Last successful update: 2026/11/20
- NMPA drug delivery notices
- Last successful update: 2026/11/20
Loaded notices dated 2026-11-06 to 2026-11-20; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.